Pricing Pressure On Drugs To Intensify As Some Enrollee Cost-Shifting Measures Plateau – PwC
Employers’ may also look more at pitting their health plan vendors against each other for cost-saving coverage, meaning drug makers face more pressure to negotiate reimbursement and other new approaches with health plans, a PwC report suggests.
You may also be interested in...
AstraZeneca VP-Market Access Rick Suarez talks about challenges and opportunities in the emerging area of innovative outcomes-based reimbursement contracts, and specifically two new contracts with Harvard Pilgrim for Bydureon and Brilinta.
Boehringer Ingelheim agreement with data analytics firm Inovalon and health care consultancy Avalere will support outcomes-based coverage deals.
Value-based, risk-sharing reimbursement contracts were a hot topic at ISPOR, but Harvard Pilgrim Health Care Chief Medical Officer Michael Sherman cautioned that finding the right drug and the right pharma partner to work with are challenging.